StockMarketWire.com - Biotechnology company ValiRx said a peer-reviewed article about one of its cancer therapies had been published in the European Journal of Drug Metabolism and Pharmacokinetics.

The journal article detailed the clinical trial results of treatment candidate VAL401.


At 8:19am: [LON:VAL] ValiRx PLC share price was 0p at 0.8p



Story provided by StockMarketWire.com